Key result
Monotherapy cholesterol-lowering drug trials consistently reported a significant 25% relative risk reduction for cardiovascular events over 2 decades.
Why the study?
Does monotherapy cholesterol-lowering drug therapy reduce cardiovascular events in primary and secondary prevention populations?
Does monotherapy cholesterol-lowering drug therapy reduce cardiovascular events in primary and secondary prevention populations?
Answers are grounded in this paper and cite their sources.
Reviews two decades of evidence showing a 25% relative risk reduction in cardiovascular events from monotherapy LDL-C-lowering drug trials, supporting ATP III guidelines and lower LDL-C goals.
It is not good to settle into a set of opinions.At first putting forth great effort to be sure that you have grasped the basics, then practicing so that they may come to fruition is something that will never stop for your whole lifetime.Do not rely on following the degree of understanding that you have discovered, but simply think. ..This is not enough."Hagakure, Yamamoto Tsunetomo, September 10, 1716 (a Samurai) 1 F or the past 22 years, substantial national efforts have been directed toward reducing the average blood low-density lipoprotein cholesterol (LDL-C) level of the American population.This initiative was initially prompted by the successful results of the Lipid Research Clinic-Coronary Primary Prevention Trial (LRC-CPPT), which first proved that reducing LDL-C resulted in a statistically significant reduction in cardiovascular events. 2 The intent of these efforts has been to reduce the human suffering and economic cost of cardiovascular disease.In the subsequent 2 decades, a plethora of monotherapy cholesterol-lowering drug trials has consistently reported a statistically significant 25% relative risk reduction for cardiovascular events.These findings form the basis for the current Adult Treatment Panel (ATP) III guidelines and the recent call to adjust the LDL-C goal even lower.
No takes yet. Share an insight, caveat, or question.
Scott M. Grundy (2008) conducted a review in Cardiovascular disease primary and secondary prevention / Elevated LDL-C. Monotherapy cholesterol-lowering drug therapy (LDL-C lowering therapy) was evaluated on Cardiovascular events (25% relative risk reduction). Monotherapy cholesterol-lowering drug trials consistently reported a significant 25% relative risk reduction for cardiovascular events over 2 decades.
Synapse has enriched 10 related papers. Consider them for comparative context: